Literature DB >> 21139307

Severe hyperglycemia induced by olanzapine was improved with a recovery of insulin secretion after switching to risperidone and introducing insulin therapy.

Masaru Nakamura1, Takahiko Nagamine.   

Abstract

A 35-year-old woman, diagnosed as schizophrenia and treated with olanzapine for nearly 30 months, consulted our department because of severe hyperglycemia. The use of antipsychotics, switching from olanzapine to risperidone, and a one-month introduction of insulin therapy resulted in the decrease of pre-prandial blood glucose levels and the increase of insulin levels (269 to 128 mg/dL, 5.6 to 21.8 µU/mL). A higher level of insulin resistance as measured by HOMA-IR after the improvement of hyperglycemia (3.6 vs. 6.8) suggested that the long use of olanzapine reduced insulin secretion. Based on this case, impairment of pancreatic β-cells caused by olanzapine might be reversible.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21139307     DOI: 10.2169/internalmedicine.49.4397

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

1.  OLANZAPINE AND DIABETIC KETOACIDOSIS: WHAT IS THE UNDERLYING MECHANISM?

Authors:  Takahiko Nagamine
Journal:  Innov Clin Neurosci       Date:  2018-04-01

Review 2.  Drug-Induced Hyperglycaemia and Diabetes.

Authors:  Neila Fathallah; Raoudha Slim; Sofien Larif; Houssem Hmouda; Chaker Ben Salem
Journal:  Drug Saf       Date:  2015-12       Impact factor: 5.606

3.  Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.

Authors:  Hoda Moteshafi; Simon Zhornitsky; Sarah Brunelle; Emmanuel Stip
Journal:  Drug Saf       Date:  2012-10-01       Impact factor: 5.606

4.  Antipsychotic olanzapine-induced misfolding of proinsulin in the endoplasmic reticulum accounts for atypical development of diabetes.

Authors:  Seiichiro Tada; Masaki Okumura; Kenta Inoguchi; Satoshi Ninagawa; Misaki Kinoshita; Shingo Kanemura; Koshi Imami; Hajime Umezawa; Tokiro Ishikawa; Robert B Mackin; Seiji Torii; Yasushi Ishihama; Kenji Inaba; Takayuki Anazawa; Takahiko Nagamine; Kazutoshi Mori
Journal:  Elife       Date:  2020-11-17       Impact factor: 8.140

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.